NasdaqGM:RAPPPharmaceuticals
Why Rapport Therapeutics (RAPP) Is Up 48.9% After Positive Phase 2a Results for RAP-219 in Seizures
Rapport Therapeutics announced positive topline results from its Phase 2a clinical trial of RAP-219 in patients with drug-resistant focal onset seizures, meeting primary and secondary efficacy endpoints with high statistical significance and a strong safety profile.
The study reported that 24% of participants experienced seizure freedom during the 8-week treatment period, an outcome that highlights significant potential for improving quality of life in this hard-to-treat patient group.
We'll...